Astrazeneca PLC (AZN) Position Increased by Schafer Cullen Capital Management Inc.

Schafer Cullen Capital Management Inc. boosted its stake in Astrazeneca PLC (NYSE:AZN) by 0.2% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 4,212,264 shares of the company’s stock after buying an additional 10,002 shares during the quarter. Astrazeneca PLC makes up about 1.8% of Schafer Cullen Capital Management Inc.’s investment portfolio, making the stock its 14th largest position. Schafer Cullen Capital Management Inc. owned 0.17% of Astrazeneca PLC worth $143,596,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds also recently made changes to their positions in the stock. Garrison Financial Corp boosted its stake in Astrazeneca PLC by 0.5% in the 2nd quarter. Garrison Financial Corp now owns 18,058 shares of the company’s stock valued at $616,000 after buying an additional 86 shares in the last quarter. Dorsey & Whitney Trust CO LLC boosted its stake in Astrazeneca PLC by 0.7% in the second quarter. Dorsey & Whitney Trust CO LLC now owns 13,315 shares of the company’s stock worth $454,000 after purchasing an additional 94 shares in the last quarter. NEXT Financial Group Inc boosted its stake in Astrazeneca PLC by 1.8% in the second quarter. NEXT Financial Group Inc now owns 6,463 shares of the company’s stock worth $220,000 after purchasing an additional 115 shares in the last quarter. Atria Investments LLC boosted its stake in Astrazeneca PLC by 0.5% in the second quarter. Atria Investments LLC now owns 24,695 shares of the company’s stock worth $842,000 after purchasing an additional 129 shares in the last quarter. Finally, Financial Counselors Inc. boosted its stake in Astrazeneca PLC by 2.7% in the second quarter. Financial Counselors Inc. now owns 6,871 shares of the company’s stock worth $234,000 after purchasing an additional 182 shares in the last quarter. 14.17% of the stock is currently owned by institutional investors and hedge funds.

A number of equities analysts have commented on the company. BidaskClub lowered Astrazeneca PLC from a “hold” rating to a “sell” rating in a research note on Monday, July 24th. Liberum Capital lowered Astrazeneca PLC from a “buy” rating to a “hold” rating in a research note on Thursday, September 14th. BNP Paribas raised Astrazeneca PLC from a “neutral” rating to an “outperform” rating in a research note on Monday, September 25th. Pareto Securities raised Astrazeneca PLC from a “sell” rating to a “hold” rating in a research note on Tuesday, August 1st. Finally, Investec raised Astrazeneca PLC from a “hold” rating to a “buy” rating in a research note on Wednesday, August 9th. Four analysts have rated the stock with a sell rating, eleven have assigned a hold rating and fourteen have issued a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and a consensus price target of $34.35.

COPYRIGHT VIOLATION NOTICE: This news story was first posted by Markets Daily and is owned by of Markets Daily. If you are reading this news story on another site, it was illegally stolen and reposted in violation of United States and international copyright laws. The legal version of this news story can be read at https://www.themarketsdaily.com/2017/10/13/astrazeneca-plc-azn-position-increased-by-schafer-cullen-capital-management-inc.html.

Astrazeneca PLC (NYSE:AZN) last issued its earnings results on Thursday, July 27th. The company reported $0.87 EPS for the quarter, beating analysts’ consensus estimates of $0.41 by $0.46. Astrazeneca PLC had a return on equity of 35.90% and a net margin of 17.80%. The business had revenue of $5.05 billion during the quarter, compared to analyst estimates of $5.04 billion. During the same period in the previous year, the company posted $0.83 EPS. The firm’s revenue was down 9.9% compared to the same quarter last year.

Astrazeneca PLC Company Profile

AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.

Want to see what other hedge funds are holding AZN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Astrazeneca PLC (NYSE:AZN).

Institutional Ownership by Quarter for Astrazeneca PLC (NYSE:AZN)

Receive News & Ratings for Astrazeneca PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Astrazeneca PLC and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply